G1G Stock Overview
A biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Zelira Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.37 |
| 52 Week High | AU$0.62 |
| 52 Week Low | AU$0.16 |
| Beta | 0.88 |
| 11 Month Change | -11.17% |
| 3 Month Change | -14.08% |
| 1 Year Change | -34.05% |
| 33 Year Change | -72.11% |
| 5 Year Change | -94.04% |
| Change since IPO | -94.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| G1G | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -9.0% | -0.3% | 0.8% |
| 1Y | -34.1% | -18.3% | 8.6% |
Return vs Industry: G1G underperformed the German Pharmaceuticals industry which returned -18.3% over the past year.
Return vs Market: G1G underperformed the German Market which returned 8.6% over the past year.
Price Volatility
| G1G volatility | |
|---|---|
| G1G Average Weekly Movement | 12.6% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G1G's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G1G's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Oludare Odumosu | zeliratx.com |
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of a variety of medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops Zenivol, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter products, including SprinJene, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology.
Zelira Therapeutics Limited Fundamentals Summary
| G1G fundamental statistics | |
|---|---|
| Market cap | €4.36m |
| Earnings (TTM) | -€22.49m |
| Revenue (TTM) | €58.40k |
74.7x
P/S Ratio-0.2x
P/E RatioIs G1G overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G1G income statement (TTM) | |
|---|---|
| Revenue | AU$94.95k |
| Cost of Revenue | AU$328.89k |
| Gross Profit | -AU$233.93k |
| Other Expenses | AU$36.33m |
| Earnings | -AU$36.57m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.22 |
| Gross Margin | -246.37% |
| Net Profit Margin | -38,513.04% |
| Debt/Equity Ratio | -135.5% |
How did G1G perform over the long term?
See historical performance and comparison